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Human epidermal growth factor receptor 2 (HER2)/Neu, which is overexpressed in about 
30% of human breast cancers, transduces growth signals in large part via the 
Ras-Raf-MEK-ERK pathway. Nevertheless, it is a matter of controversy whether high ERK 
activity in breast cancer tissues correlates with better or worse prognosis, leaving the role of 
ERK activity in the progression of breast cancers unresolved. To address this issue, we 
live-imaged ERK activity in mammary tumors developed in mouse mammary tumor virus 
(MMTV) - Neu transgenic mice, which had been crossed with transgenic mice expressing a 
FRET biosensor for ERK. Observation of the tumor by two-photon microscopy revealed 
significant heterogeneity in ERK activity among the mammary tumor cells. The level of ERK 
activity in each cell was stable up to several hours, implying a robust mechanism that 
maintained the ERK activity within a limited range. By sorting the mammary tumor cells 
based on their ERK activity, we found that ERKhigh cells less efficiently generated 
tumorspheres in vitro and tumors in vivo than did ERKlow cells. In agreement with this finding, 
the expressions of the cancer-stem-cell markers CD49f, CD24, and CD61 were decreased in 
ERKhigh cells. These observations suggest that high ERK activity may suppress the 
self-renewal of mammary cancer stem cells.  
 
INTRODUCTION 
Cancer cells display phenotypic and functional heterogeneity. The concept of cancer stem cells 
(CSCs)/tumor initiating cells (TICs) is a representative example of such heterogeneity within a 
single tumor 1. CSCs/TICs have the ability to self-renew and generate a diverse range of tumor 
cells, and thus serve as promising anti-cancer drug targets 2. Nevertheless, methods to study 
CSCs/TICs in vivo are limited because the identification of CSCs/TICs depends on the 
expression of cell surface markers. 
Human epidermal growth factor receptor 2 (HER2)/Neu is overexpressed in some 30% of 
breast cancers and associated with poor prognosis 3. It has been suggested that HER2/Neu may 
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regulate the CSC/TIC property. In HER2-overexpressing carcinoma cell lines, cells with a 
CSC/TIC property presented increased HER2 levels compared with the bulk cell population 4. 
HER2 overexpression in normal mammary epithelial cells increases the proportion of stem and 
progenitor cells 5. In line with these observations, it has been shown that the effects of HER2 
overexpression on breast cancer stem cells are blocked by the HER2 inhibitor trastuzumab 4, 5. 
Moreover, overexpression of the polycomb protein EZH2, which has been linked to breast 
cancer progression, causes RAF1 amplification and, thereby, ERK activation to promote 
CSC/TIC expansion 6. 
The receptor-type tyrosine kinases, including HER2/Neu, transduce growth signals in large 
part via the Ras-Raf-MEK-ERK pathway 7. In mouse mammary tumor virus (MMTV)- Neu 
transgenic mice, which are widely used as a mouse model of HER2/Neu-positive luminal-type 
breast cancer 8, 9, ERK regulates the self-renewal of mammary stem and progenitor cells by 
upregulation of cyclin D1 kinase activity 10 and contributes to malignancy by increasing the 
activity of the Notch pathway 11. ERK also regulates many other cancer cell phenotypes, such 
as invasion and metastasis 7. In agreement with these observations, high ERK activity in breast 
cancer tissues has been shown to correlate with poor prognosis of patients 12. It has also been 
reported that activation of the ERK pathway drives resistance to paclitaxel 13.  
Surprisingly, however, in some clinical studies high ERK activity in breast cancer tissues is 
associated with improved survival 14-16. This seemingly contradictory observation might 
involve the inhibitory effect of ERK on the self-renewal of stem cells 17, 18. Even though the 
inhibitory role of ERK on maintenance of the undifferentiated state is cell type-specific 19, it 
should be of great concern whether ERK plays a positive or negative role in the self-renewal 
of CSCs/TICs of mammary tumors, considering the fact that many anti-cancer drugs target 
the HER2/Neu-Ras-ERK pathway. To answer this question, we visualized the ERK activity in 
mammary tumors developed in MMTV- Neu transgenic mice that had been crossed with 
transgenic mice expressing a Förster resonance energy transfer (FRET) biosensor for ERK 20. 
Observation of the transgenic mice by two-photon (2P) microscopy revealed significant 
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heterogeneity in ERK activity among the primary breast cancer cells. By sorting the mammary 
tumor cells based on their ERK activity, we found that ERKhigh cells generated tumorspheres in 
tissue culture and tumors after orthotopic implantation less efficiently than did ERKlow cells.  
 
RESULTS AND DISCUSSION 
Heterogeneity in ERK activity as visualized by in vivo FRET imaging  
To study the role of ERK activity in mammary tumors, we crossed MMTV-Neu+/+ mice 
with EKAREV+/- mice, which express a FRET biosensor for ERK, EKAREV 21. With 
EKAREV+/- mice, ERK activity in mouse tissues can be visualized by the YFP/CFP ratio 
image (Supplementary Fig. S1A). The obtained EKAREV+/-/MMTV-Neu+/- mice were 
indistinguishable from the parent MMTV-Neu+/- mice in size, the susceptibility to mammary 
tumor development, and the histological appearance of the developed tumors. We first 
observed normal mammary glands of EKAREV+/- mice by 2P microscopy (Fig. 1A). The 
EKAREV biosensor was expressed both in luminal epithelial cells and myoepithelial cells. 
The level of ERK activity was higher in myoepithelial cells than luminal epithelial cells. 
Tissue autofluorescence of mammary tissues was negligible in our experimental setup 
(Supplementary Fig. S1B, C).  
The EKAREV+/-/MMTV-Neu+/- mice developed mammary tumors from 24 weeks after 
birth. We found that tumor cells exhibited significant heterogeneity in ERK activity without 
forming any clusters with similar activity levels (Fig. 1B). The standard deviations of the 
FRET/CFP ratio of luminal epithelial cells and mammary tumors were 0.069 and 0.13, 
respectively (Fig. 1A, B). There was no correlation between the FRET signal and the 
expression level of the biosensor, suggesting that the divergence in the FRET signal of 
mammary tumor cells indeed reflected the heterogeneity in the ERK activity (Fig. 1C). We 
confirmed the heterogeneity in the ERK activity by immunostaining with an 
anti-phospho-ERK antibody (Fig. 1D).  
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To examine whether such diversity in ERK activity was caused by temporal noise or 
population noise, the mammary tumor cells were live-imaged for six hours. The ERK 
activities relative to the average for the cell population did not change remarkably in most 
cells during the course of observation, suggesting that each tumor cell maintained ERK 
activity homeostasis within a limited range by means of a robust mechanism (Figure 1E, 
Supplementary Fig. S1D).  
 
Real-time pharmacodynamics of anti-cancer drugs against ERK activity in the primary 
and secondary tumors 
The heterogeneity in the ERK activity among tumor cells inspired us to examine its 
biological meaning. To investigate this issue, mice bearing the mammary tumors were 
administered with several anti-cancer drugs. To gain insight into the role of 
microenvironments, in addition to the primary mammary tumors (P0) we also used passaged 
mammary tumors (P1), which appeared in one month after the injection of the primary tumor 
into the mammary fat pad of syngeneic FVB mice. The MEK inhibitor PD0325901 
immediately suppressed ERK activity in both the P0 mammary tumor cells and the P1 
mammary tumor cells with a half-time of ca. 10 min (Fig. 2A, B). We observed no remarkable 
differences in the response to PD0325901 between cells close to and those remote from the 
blood vessels, which were visualized by Qtracker 655 co-injected with the reagents. Notably, 
the decrease in ERK activity was larger in cells with higher ERK activity than in cells with 
lower ERK activity (Supplementary Fig. S2A). The low-ERK-activity cells in the P0 tumors 
appeared to be the least-responsive cell population. Lapatinib, a dual tyrosine kinase inhibitor 
against epidermal growth factor receptor (EGFR) and epidermal growth factor receptor 2 
(HER2), gradually decreased the ERK activity from 10 min after injection in both the P0 
mammary tumor cells and the P1 mammary tumor cells (Fig. 2C, D). Again, the 
low-ERK-activity cells in the P0 tumors responded to Lapatinib least efficiently 
(Supplementary Fig. S2A). To examine whether the delay might have been caused by the 
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difference in the pharmacokinetics, we examined the effect of PD0325901 and Lapatinib in 
vitro with primary mammary tumor cells derived from the transgenic mice (Supplementary 
Fig. S2B). As observed in vivo, ERK activity in the Lapatinib-treated cells started decreasing 
with ca. 5 minutes delay, suggesting that the delay was caused by the sensitivity of the tumor 
cells to Lapatinib. With the in vitro tumor cells, we also examined the response of mammary 
tumor cells to EGF. In contrast to the response to the inhibitors, any significant correlation 
was not observed between the basal ERK activity and the EGF-induced increment 
(Supplementary Fig. S2C). Taken together, these results imply that the heterogeneity in ERK 
activity in mammary tumor cells may contribute to the difference in the sensitivity to 
anti-cancer drugs.  
In vivo imaging of protein kinase activity by 2P microscopy has opened a new window for 
the assessment of pharmacodynamics. With transgenic mice expressing FRET biosensors, the 
effect of an MEK inhibitor on the ERK activity of neutrophils or the effect of a cAMP 
analogue on the PKA activity of muscles and neurons has been video-imaged in living mice 21. 
More recently, the effect of dasatinib on Src activity has also been visualized with 
subcutaneously implanted pancreatic cancer cells that stably express a FRET biosensor for 
Src 22. Here, we showed the drug sensitivity of the mammary tumors developed in MMTV- 
Neu transgenic mice. We chose PD0325901 and Lapatinib, which are a non-ATP-competitive 
MEK inhibitor under phase I trial 23 and a dual tyrosine kinase inhibitor of EGFR and HER2 
in clinical use 24, respectively. Upon intravenous injection of inhibitors of MEK or HER2, the 
ERK activity decreased more significantly in high-ERK-activity cells than in 
low-ERK-activity cells (Fig. 2). Based on this observation, we may be able to speculate that 
the inhibitors of the HER2/Neu-ERK pathway are less effective for treatment of 
low-ERK-activity cells. 
 
Decreased tumorsphere formation efficiency and expression of cancer stem cell markers 
in tumor cells with high ERK activity 
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To elucidate the role of the heterogeneity of ERK activity among mammary tumor cells, we 
sorted the cells based on their ERK activity (Fig. 3A). A fluorescent dye that accumulates in 
dead cells, 7AAD, was included to select for live cells. After selecting single living cells with 
the forward scatter and side scatter signals, biosensor-expressing cells were identified by the 
CFP and YFP signals. For cell sorting, the FRET/CFP ratio was used as the index of FRET 
efficiency as in 3D imaging. Mammary tumor cells in the highest and lowest decile with 
respect to the FRET/CFP ratio were named the ERKhigh and ERKlow populations, respectively 
(Fig. 3A). We next compared the biological activity by a tumorsphere formation assay (Fig. 
3B). The ERKhigh population exhibited lower tumorsphere formation efficiency (0.3±0.2%) 
compared with the ERKlow population (1.3±0.2%). To understand the role of ERK in 
tumorsphere formation, we followed the ERK activity of ERKhigh and ERKlow cell populations 
in vitro. The fraction of high-ERK-activity cells in the ERKhigh population decreased within 
nine days to the level of those of the ERKlow population (Supplementary Fig. S3A). Timelapse 
imaging revealed that the high-ERK-activity cells died within three days (Supplementary Fig. 
S3B), implying that the low tumorsphere formation efficiency of ERKhigh cells is at least 
partially attributable to the vulnerability of ERKhigh cell. The ERKhigh and ERKlow populations 
were further analyzed by an in vivo transplantation assay (Fig. 3C). Again, the ERKhigh 
population yielded tumors less efficiently than did the ERKlow population. Because the 
tumorsphere formation assay and the transplantation assay were used to examine the stem cell 
property of cancer cells, these results strongly suggested that high ERK activity may suppress 
the stemness of mammary tumor cells. 
To explore this possibility, we examined the expression of mammary stem cell markers on 
the ERKhigh and ERKlow cell populations. As reported previously 25, 26, a large portion of the 
MMTV-Neu tumor cells expressed three mammary stem cell markers, CD49f, CD24, and 
CD61 (Fig. 3D). We found that CD61-/CD49f- cells or CD24-/CD49f- cells were significantly 
increased in the ERKhigh population, suggesting that high ERK activity may suppress the stem 
cell property of mammary tumor cells. The percentage of CD61-/CD49f- cells or 
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CD24-/CD49f- cells in the ERKhigh population varied depending on the mouse age, but the 
pattern was similar in multiple mice (N = 3), showing a reproducible decrease in 
CD61-/CD49f- cells or CD24-/CD49f- cells in the ERKhigh population of MMTV-Neu 
mammary tumor cells. 
Finally, we attempted to increase mammary tumor cells bearing the stem cell property by 
the pretreatment of mice bearing the tumors with the MEK inhibitor. Against our expectation, 
we failed to observe the decrease in the ERK activity of P0 mammary tumor cells by the daily 
administration of the MEK inhibitor PD0325901 (Fig. 4A). The discrepancy between the data 
by FRET imaging (Fig. 2) and the anti-phospho-ERK immunoblotting could be explained by 
several reasons. First, the variation in the ERK activity of each tumor could be greater than 
the effect of PD0325901 on each tumor. Second, the daily administration of PD0325901 to 
the tumor-bearing mice could render the tumor cells resistant to this compound. Third, the 
FRET biosensor detects the phosphorylation level of the ERK substrates; whereas 
anti-phospho-ERK immunoblotting detects the phosphorylation of ERK.  
Notably, however, the ERK activity in each tumor correlated inversely with the expression 
levels of CD24 and CD61, but not of CD49f (Fig. 4B), and also with the tumorsphere 
formation efficiency (Fig. 4C), suggesting that high ERK activity suppresses the cancer stem 
cell property. The failure to suppress ERK activity in vivo urged us to use J3B1 cells, which 
are derived from the non-tumorigenic murine EpH4 mammary epithelial cell line 27. We found 
that PD0325901 suppressed ERK activity and increased the expression of CD24 and CD61 
(Supplementary Fig. S4), indicating that ERK negatively regulated the expression of CD24 
and CD61. Again, CD49f expression was not affected by the decrease in the ERK activity. 
Altogether, these observations are compatible with the proposal that high ERK activity 
suppresses the cancer stem cell property in the MMTV-Neu mammary tumor model. 
Previous studies have identified CD24, CD49f, and CD61 as markers of the mammary stem 
cells and/or luminal progenitor cells 28-31. The identified markers have also been used to purify 
CSCs/TICs in MMTV-Neu mice. Liu et al. demonstrated a dramatic increase in the 
 9 
 
CD49f+CD24+ population in mammary tumors, which efficiently form tumorspheres 25. In the 
initial attempt to use CD61 as a CSC/TIC marker, Vaillant et al. did not find significant 
enrichment of CSCs/TICs in the CD61high population 32; however, a later study identified the 
CD49fhighCD61high-sorted fraction as a TIC-enriched population of MMTV-Neu mice, which 
displayed increased tumorsphere formation ability, enhanced tumorigenicity in vivo and drug 
resistance to paclitaxel and doxorubicin 26. We found that ERKhigh cells exhibited not only the 
decrease of cells that were positive for CD49f, CD24, and CD61 but also a decrease of the 
tumorsphere efficiency in vitro and tumor formation efficiency in the fat-pad injection assay 
(Fig. 3). Furthermore, ERK activity in mammary tumors inversely correlated with the 
expression level of CD24 and CD61 and the tumorsphere formation efficiency (Fig. 4). In 
mouse ES cells, it has been established that ERK activity must be suppressed for the 
elimination of differentiation-inducing signaling 33. In agreement with this report, we found 
that mammary tumor cells with higher ERK activity were selectively eliminated in vitro 
(Supplementary Fig. S4). Thus, low ERK activity may be beneficial for self-renewal of the 
CSCs/TICs of mammary tumor cells as in EC cells. 
It has been established that ERK plays critical roles in the expansion of CSCs/TICs of 
breast cancer 6, 10, 11. Intuitively, this observation would seem to undermine the finding that 
ERKhigh cells isolated from mammary tumor tissues were less tumorigenic than ERKlow cells 
(Fig. 3). Previous studies have demonstrated the roles of ERK by comparing cells with and 
without oncogene expression, indicating that the cancer cell population, on average, shows 
high ERK activity, rapid cell growth, and enrichment of CSCs/TICs in comparison to control 
cells. Therefore, it is plausible that, within breast cancer tissues, the cell population with 
lower ERK activity is enriched in CSCs/TICs and that the cell population with higher ERK 
activity is enriched in rapidly-expanding and, at the same time, vulnerable cells. 
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Figure 1. Heterogeneity in ERK activity as visualized by in vivo FRET imaging. A, The 
transgenic mice expressing an ERK FRET biosensor EKAREV were reported previously 21. 
Founder animals were backcrossed with FVB/N for at least two generations before crossing 
with MMTV-Neu+/+ mice (FVB/N; Jackson’s Lab). Mice were anesthetized with 1.5% 
inhalation of isoflurane (Abbott) at 0.5 L/min. Surgical exposure of a tissue flap containing the 
mammary gland was performed as described previously 34. The mammary gland in a 
twelve-week-old female EKAREV+/- mouse was observed under an IX81/FV1000 inverted 
microscope equipped with a x30 silicon oil-immersion objective lens (UPLSAPO 30xS; 
Olympus), which was connected to a Mai Tai DeepSee HP Ti: Sapphire Laser (Spectra Physics). 
The excitation wavelength was 840 nm. Acquired images were analyzed with MetaMorph 
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software (Universal Imaging) and Imaris Software (Bitplane AG) as described previously 21, 35. 
An XY slice, a scheme, and an enlarged FRET/CFP ratio image are shown. The FRET/CFP 
ratio image is shown in intensity-modulated (IMD) display mode. In the IMD mode, eight 
colors from red to blue are used to represent the FRET/CFP ratio, with the intensity of each 
color indicating the mean intensity of FRET and CFP. The upper and lower limits of the ratio 
range are shown at the bottom of the figure. The FRET/CFP ratios of myoepithelial cells (Myo, 
N = 32) and luminal cells (Lumi, N = 90) are shown in the histogram. B, A FRET image of 
mammary tumors developed in EKAREV+/-/MMTV-Neu+/- mice and observed under the 2P 
microscope. C, The CFP intensity and FRET/CFP value in each primary tumor cell were plotted 
(N = 50). D, Immunostaining of a mammary tumor. Paraffin-embedded sections were fixed 
with 4% paraformaldehyde, blocked with 3% BSA, incubated with an anti-phosphor-ERK 
antibody (1:200; cat. no. 4370S; Cell Signaling), and further incubated with Alexa 
546-conjugated anti-rabbit IgG (1:1000; no.A-11035; Life Technologies). The section was 
imaged under a fluorescent microscope. E, Mammary tumors in EKAREV+/-/MMTV-Neu+/- 
mice were timelapse-imaged for 6 hours under a 2P microscope. Red or blue lines represent the 
time courses of the top or bottom 12.5% of cells (five cells each). P value was calculated using 
a two tailed Student’s t test. 
 
Figure 2. Timelapse in vivo imaging of ERK activity in EKAREV+/-/MMTV-Neu+/- mice 
treated with an MEK or a tyrosine kinase inhibitor. The primary tumors in 
EKAREV+/-/MMTV-Neu+/- mice and the secondary tumors in syngeneic mice were observed 
by 2P microscopy. A, A MEK inhibitor, PD0325901, was injected intravenously (5 mg/kg) at 
time zero. The white-boxed regions are magnified in the right panels. B, FRET/CFP ratios of 
individual cells were plotted against time. The red and blue lines indicate cells belonging to 
the top and bottom 12.5%, respectively, at the beginning of imaging (N =40). C and D, An 
EGFR/HER2 dual tyrosine kinase inhibitor, Lapatinib, was injected intravenously (50 mg/kg) 
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at time zero. Data were obtained as in A and B (N =40). Error bars indicate SD. Scale bars, 20 
m. 
 
Figure 3. Characteristics of the ERKhigh and ERKlow populations. Mammary tumors were 
dissected from EKAREV+/-/MMTV-Neu+/- mice to obtain a single-cell suspension essentially as 
described previously 36. Briefly, a portion of the tumor was minced into small pieces with sterile 
scissors, washed in PBS, digested in collagenase/trypsin for 30 min at 37oC with occasional 
mixing, and washed once with DMEM/F12 (Life Technologies). Mammary epithelial cells 
were enriched by Mouse Epithelial Cell Enrichment kit (StemCell Technologies). 
Single-epithelial cell suspensions were resuspended in L-15 Medium (Life Technologies) and 
analyzed and/or sorted with a FACSAria (Becton Dickinson). A, Representative FACS dots 
plots showing the biosensor-expressing mammary tumor cells developed in 
EKAREV+/-MMTV-Neu+/- mice. Mammary tumor cells in the highest and lowest decile with 
respect to the FRET/CFP ratio were named the ERKhigh and ERKlow populations, respectively. 
The sorted ERKhigh and ERKlow cells were re-analyzed for the validation of the sorting (shown 
in red and blue histograms, respectively). B, The ERKhigh and ERKlow cells were plated in 
poly-HEMA-treated six-well plates (Becton Dickinson) at a density of 10,000 cells/ml in 
phenol red-free Mammary Epithelial Cell Basal Medium (Takara Bio, Kyoto, Japan) 
supplemented with 20 ng/ml EGF (Sigma), 20 ng/ml basic fibroblast growth factor (Sigma), 5 
g/ml insulin (Sigma), and 2% B27 supplement (Life Technologies). The tumorsphere 
formation was evaluated two weeks after plating. The result represents averages of three 
biological replicates. C, The ERKhigh and ERKlow cells (50 cells each) were injected into fat 
pads of syngeneic mice. Development of tumors was assessed three months after inoculation. D, 
Representative flow cytometric profiles for CD24/CD49f or CD61/CD49f were obtained from 
ERKhigh and ERKlow populations in two representative primary tumors (N = 4). We used 
anti-CD49f antibody conjugated with Alexa-647 or PE/Cy7 (BioLegend), anti-CD24 antibody 
conjugated with PE/Cy7 (BioLegend), and anti-CD61 antibody conjugated with Alexa-647 
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(BioLegend). Error bars indicate S.D. P value was calculated using a two tailed Student’s t 
test. 
 
Figure 4. Inverse correlation of ERK activity with the expression of the cancer stem cell 
markers. EKAREV+/-MMTV-Neu+/- mice bearing mammary tumors were orally administered 
with 50 mg/kg PD0325901 for one week. Single-cell suspension of tumor cells were prepared 
as described in the legend to Figure 3. A, Part of cells was subjected to immunoblotting 
analysis with anti-phospho-ERK antibody or anti-tubulin antibody (Calbiochem). B, 
Expression of cancer stem cell markers were examined as described in the legend to Fig. 3. 
Mode values of cells treated with PD0325901 was divided by those without PD0325901 to 
show the expression level. C, The suspended cells were plated in poly-HEMA-treated six-well 
plates at a density of 10,000 cells/ml as described in the legend to Figure 3. The tumorsphere 
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Figure S1. Supplementary information to Figure 1, "Heterogeneity in ERK activity as visualized by in vivo FRET 
imaging." 
(A), A FRET biosensor, EAKREV-NES, changes its conformation and increases FRET efficiency upon 
phosphorylation by ERK. YFP, a yellow fluorescent protein used as a FRET acceptor; CFP, a cyan fluorescent protein 
used as a FRET donor; FHA1, a phospho-threonine recognition domain; ERK substrates, substrates specific for ERK; 
NES, nuclear export sequence. 
(B and C), A transgenic mice expressing EKAREV and a control FVB/N mice were anesthetized and imaged as 
described in the legend to Figure 1, except that 10 µl Qtracker 655 was injected intravenously to visualize blood vessels. 
Images were divided into 506 regions, of which CFP and FRET intensities are shown in panel (C). 
(D), Fifty mammary tumor cells in Fig. 1C were timelapse-imaged for 6 hours under a 2P microscope. The red, green, 
and blue dotted lines indicate the FRET/CFP ratios, 0.9, 0.8, and 0.7, respectively. Panels with red and blue lines are 
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Figure S2. Supplementary information to Figure 2, "Time-lapse in vivo imaging of ERK activity in 
EKAREV+/-/MMTV-Neu+/- mice treated with an MEK or a tyrosine kinase inhibitor." 
(A), The decreases in FRET/CFP values 90 minutes after intravenous injection of PD0325901 or Lapatinib are plotted 
against the FRET/CFP values before drug injection. 
(B), Response to PD0325901 in vitro. Tumor cells were prepared as described in the legend to Figure 3, plated on 35 
mm-diameter glass-base dishes, cultured two days in DMEM/F12 containing 5% FBS. Inhibitors, 1 µM PD0325901 or 
10 µM Lapatinib, was added at time zero. Cells were imaged at 37oC in 5% CO2 with an inverted microscope (IX81; 
Olympus, Tokyo, Japan) equipped with a x60 objective lens (PlanApoPH/NA 1.40; Olympus), a cooled CCD camera 
(Cool SNAP-K4; Roper Scientific, Tucson, AZ), an LED illumination system (CoolLED precisExcite; Molecular 
Devices, Sunnyvale, CA), an IX2-ZDC laser-based autofocusing system (Olympus) and an MD-XY30100T-Meta 
automatically programmable XY stage (SIGMA KOKI, Tokyo, Japan). The following filters used for the dual emission 
imaging studies were obtained from Omega Optical (Brattleboro, VT): an XF1071 (440AF21) excitation filter, an 
XF2034 (455DRLP) dichroic mirror, and two emission filters, XF3075 (480AF30) for CFP and XF3079 (535AF26) for 
yellow fluorescent protein (YFP). After background subtraction, FRET/CFP ratio images were created with MetaMorph 
software (Universal Imaging, West Chester, PA), and represented by intensity-modulated display mode. Error bar 
indicates S.D. (N = 20).
(C), Response to EGF in vitro. Cells were prepared as in (B). EGF (10 ng/ml) was added at time zero. Red and blue 
lines indicate the time-courses of four cells showing the highest or lowest basal ERK activity. The increases in the 
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Figure S3. Supplementary information to Fig. 3, "Characteristics of the ERKhigh and ERKlow populations." 
(A), ERKhigh and ERKlow cells were prepared as described in the legend to Fig. 3. Cells were embedded in 7.5 mg/ml 
growth factor-reduced Matrigel (BD), cultured in DMEM/F12 medium containing 5% FBS and imaged with an FV10i 
laser scanning confocal microscope (Olympus, Tokyo, Japan) for 9 days. The FRET/CFP values at Day 1, 2, and 9 were 
examined for at least 12 cells in each condition. 
(B), Tumor cells before sorting were plated on Matrigel-coated 35 mm-diameter glass-base dishes and cultured in 
DMEM/F12 containing 5% FBS for 3 days. For the visualization of dead cells, 7AAD (1:200) was included. Cells were 
imaged with an FV1000 inverted confocal microscope (Olympus, Tokyo, Japan). Arrows are used to show the identical 
cells. Scale bar, 20µm
Figure S4. Supplementary information to Fig. 4, "Inverse correlation of ERK activity with the expression of cancer 
stem cell markers." J3B1 mouse mammary epithelial cells were cultured in the presence or absence of 1 µM 
PD0325901 for two days. 
(A), Part of cells was subjected to immunoblotting analysis with anti-phopho-ERK antibody or anti-tubulin antibody. 
Error bar indicates S.D. (N = 4). 
(B), With the remaining cells, expression of cancer stem cell markers were examined as described in the legend to Fig. 
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